MiMedx Group Inc has a consensus price target of $13.83 based on the ratings of 6 analysts. The high is $23 issued by Northland Capital Markets on July 26, 2021. The low is $11 issued by Cantor Fitzgerald on July 2, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, HC Wainwright & Co., and Lake Street on July 2, 2024, May 1, 2024, and March 7, 2024, respectively. With an average price target of $11.33 between Cantor Fitzgerald, HC Wainwright & Co., and Lake Street, there's an implied 58.29% upside for MiMedx Group Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/02/2024 | Buy Now | 53.63% | Cantor Fitzgerald | Ross Osborn | → $11 | Initiates | → Overweight | Get Alert |
05/01/2024 | Buy Now | 53.63% | HC Wainwright & Co. | Swayampakula Ramakanth | → $11 | Reiterates | Buy → Buy | Get Alert |
03/07/2024 | Buy Now | 67.6% | Lake Street | Brooks O'Neil | → $12 | Initiates | → Buy | Get Alert |
03/01/2024 | Buy Now | 95.53% | Mizuho | Anthony Petrone | $13 → $14 | Maintains | Buy | Get Alert |
10/31/2023 | Buy Now | 67.6% | Mizuho | Anthony Petrone | $14 → $12 | Maintains | Buy | Get Alert |
10/27/2023 | Buy Now | 67.6% | Craig-Hallum | Chase Knickerbocker | → $12 | Initiates | → Buy | Get Alert |
08/02/2023 | Buy Now | 67.6% | Mizuho | Anthony Petrone | $10 → $12 | Maintains | Buy | Get Alert |
08/02/2023 | Buy Now | 53.63% | HC Wainwright & Co. | Swayampakula Ramakanth | $8 → $11 | Maintains | Buy | Get Alert |
06/21/2023 | Buy Now | 11.73% | HC Wainwright & Co. | Swayampakula Ramakanth | $9.5 → $8 | Maintains | Buy | Get Alert |
05/03/2023 | Buy Now | 32.68% | HC Wainwright & Co. | Swayampakula Ramakanth | $8 → $9.5 | Maintains | Buy | Get Alert |
03/02/2023 | Buy Now | 11.73% | HC Wainwright & Co. | Swayampakula Ramakanth | → $8 | Reiterates | → Buy | Get Alert |
10/13/2022 | Buy Now | -2.23% | Mizuho | Anthony Petrone | → $7 | Initiates | → Buy | Get Alert |
09/07/2022 | Buy Now | 11.73% | HC Wainwright & Co. | Swayampakula Ramakanth | $8.5 → $8 | Maintains | Buy | Get Alert |
09/14/2021 | Buy Now | 18.72% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Maintains | Buy | Get Alert |
07/26/2021 | Buy Now | 221.23% | Northland Capital Markets | Carl Byrnes | — | Initiates | → Outperform | Get Alert |
The latest price target for MiMedx Group (NASDAQ:MDXG) was reported by Cantor Fitzgerald on July 2, 2024. The analyst firm set a price target for $11.00 expecting MDXG to rise to within 12 months (a possible 53.63% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for MiMedx Group (NASDAQ:MDXG) was provided by Cantor Fitzgerald, and MiMedx Group initiated their overweight rating.
There is no last upgrade for MiMedx Group
There is no last downgrade for MiMedx Group.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MiMedx Group, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MiMedx Group was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
While ratings are subjective and will change, the latest MiMedx Group (MDXG) rating was a initiated with a price target of $0.00 to $11.00. The current price MiMedx Group (MDXG) is trading at is $7.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.